Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that on March 10, 2025, the Company ...

Inspira Technologies (IINN) announced positive results from the clinical study of its AI-powered HYLA blood sensor. The HYLA achieved 96% ...

Inspira Technologies' HYLA blood sensor achieves 96% accuracy in clinical study, paving the way for FDA submission by 2025.

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced positive results from the clinical ...

The clinical study involved 6 patients undergoing open-heart surgery with the clip-on HYLA blood sensor attached at two different points on the blood circuit tubing, allowing monitoring of the ...

The Company is proud to report that the HYLA successfully achieved 96% accuracy in its clinical study results for a key parameter, as compared to traditional blood test analyzers. In addition ...

Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies (NASDAQ:IINN) announced, on Tuesday, positive results from the clinical study of its AI-powered HYLA blood sensor. The company reported that the HYLA successfully achieved 96% ...

Inspira Technologies' innovative blood sensor is gaining attention. According to a recent announcement, results from the ...

Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission ...